XML 21 R8.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Revenue
6 Months Ended
Jun. 30, 2024
Revenue  
Revenue

2.        Revenue

The Company launched LOQTORZI in December 2023, YUSIMRY in July 2023 and CIMERLI in October 2022. Net revenue for sales of YUSIMRY and CIMERLI effectively ceased to be recognized in the Company’s condensed consolidated statements of operations on June 26, 2024 and March 1, 2024, respectively (see Note 6. Acquisition and Dispositions). All net product revenue was generated in the United States, and the Company’s net revenue was as follows:

Three Months Ended

Six Months Ended

June 30, 

June 30, 

(in thousands)

    

2024

2023

2024

    

2023

Products

UDENYCA

$

50,917

$

31,729

$

93,584

$

57,908

CIMERLI

26,728

28,194

32,902

YUSIMRY

3,766

7,660

LOQTORZI

3,789

5,777

Total net product revenue

58,472

58,457

135,215

90,810

Other revenue

 

6,507

 

259

 

6,827

 

342

Total net revenue

$

64,979

$

58,716

$

142,042

$

91,152

Gross product revenues by significant customer as a percentage of total gross product revenues were as follows:

    

Three Months Ended

Six Months Ended

 

June 30, 

June 30, 

2024

 

2023

2024

 

2023

 

McKesson Corporation

 

38

%

34

%

40

%

34

%

Cencora (previously known as AmeriSource-Bergen Corporation)

 

41

%

50

%

41

%

47

%

Cardinal Health, Inc.

 

19

%

14

%

17

%

17

%

Product Sales Discounts and Allowances

The total provision related to sales made in the prior period was $2.8 million and $3.1 million for the three months ended June 30, 2024 and 2023, respectively. Chargebacks and discounts for prompt payment are recorded as a reduction in trade receivables, and the remaining reserve balances are classified as current liabilities and other liabilities, non-current on the accompanying unaudited condensed consolidated balance sheets.

In connection with the Sale Transactions, the Company retained and will continue to be responsible for sales discounts and allowance liabilities incurred prior to March 1, 2024 for CIMERLI and June 26, 2024 for YUSIMRY. Sales discounts and allowances incurred on behalf of the respective counterparties following the close of the Sale Transactions in accordance with the Company’s Transition Services Agreement with Sandoz (the “CIMERLI TSA”) in March 2024 for CIMERLI and the Company’s Transition Services Agreement with HKF (the “YUSIMRY TSA” and, together with the CIMERLI TSA, collectively the “TSA”) in June 2024 for YUSIMRY are reflected within TSA receivables, net and TSA payables and other accrued liabilities in the unaudited condensed consolidated balance sheets and are excluded from the below table (see Note 6. Acquisition and Dispositions).

The activities and ending reserve balances for each significant category of discounts and allowances that constitute variable consideration were as follows:

Six Months Ended June 30, 2024

    

Chargebacks

    

    

Other Fees,

    

and Discounts

Co-pay

for Prompt

Assistance

(in thousands)

Payment

Rebates

and Returns

Total

Balances at December 31, 2023

$

73,953

$

121,137

$

49,795

$

244,885

Provision related to sales made in:

Current period

486,139

109,615

80,252

676,006

Prior period - increase (decrease)

(816)

6,145

(1,263)

4,066

Payments and customer credits issued

 

(485,633)

(105,986)

(82,240)

(673,859)

Balances at June 30, 2024

$

73,643

$

130,911

$

46,544

$

251,098

Six Months Ended June 30, 2023

    

Chargebacks

    

    

Other Fees,

    

and Discounts

Co-pay

for Prompt

Assistance

(in thousands)

Payment

Rebates

and Returns

Total

Balances at December 31, 2022

$

42,677

$

38,713

$

19,113

$

100,503

Provision related to sales made in:

Current period

 

226,074

45,009

37,936

309,019

Prior period - increase (decrease)

(1,380)

1,059

3,830

3,509

Payments and customer credits issued

 

(217,014)

 

(27,332)

 

(34,118)

 

(278,464)

Balances at June 30, 2023

$

50,357

$

57,449

$

26,761

$

134,567